/
ICUI
$147.93-$0.34 (-0.23%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.7B
25M shares
52-week range
$107.00 – $160.29
77% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
3.18%
Moderate
Price (6 mo)
Loading chart…
Change$-60.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.27B | $1.27B | $1.32B | $2.28B | $2.26B | $2.38B | $2.23B |
| Cost of revenue | $830.0M | $794.3M | $809.5M | $824.8M | $1.58B | $1.52B | $1.56B | $1.41B |
| Gross profit | $570.0M | $471.9M | $461.5M | $491.5M | $697.8M | $739.9M | $824.8M | $819.7M |
| Gross margin | 40.7% | 37.3% | 36.3% | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% |
| R&D | $52.9M | $48.6M | $42.9M | $47.5M | $93.0M | $85.3M | $88.6M | $87.5M |
| Operating income | $21.6M | $107.4M | $98.2M | $123.2M | −$42.9M | $22.8M | $43.0M | $107.0M |
| EBITDA | $271.9M | $192.2M | $194.1M | $223.5M | $191.5M | $253.2M | $43.0M | $326.5M |
| Net income | $28.8M | $101.0M | $86.9M | $103.1M | −$74.3M | −$29.7M | −$117.7M | $732.0K |
| Net margin | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
| EPS (diluted) | 1.33 | 4.69 | 4.02 | 4.74 | -3.11 | -1.23 | -4.83 | 0.03 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.2B | $8.16 | $8.14–$8.19 | 6 |
| 2027 | $2.3B | $9.27 | $9.12–$9.44 | 6 |
| 2028 | $2.4B | $10.15 | $6.96–$11.80 | 3 |
| 2029 | $2.3B | $10.50 | $10.36–$10.64 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
ICU Medical Inc
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
www.icumed.com- Employees
- 13,000
- IPO / List date
- Mar 31, 1992
- HQ
- SAN CLEMENTE, CA
Held by traders on TradeandTell
No one on the platform currently holds ICUI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 11,309 | $1.5M |
| Bridgewater Associatesas of 2024-12-31 | 2,415 | $374.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ICUI yet.
